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ABSTRACT 
RAC3 is a coactivator of steroid receptors and NF-B. It is usually overexpressed in several tumors, contributes 
to maintain cancer stem cells and also to induce them when is overexpressed in non-tumoral cells. In this work, 
we investigated whether the inflammatory cytokine TNF may contribute to the transforming effects of RAC3 
overexpression in the non-tumoral HEK293 cell line.  
The study model included the HEK293 tumoral transformed cell line constitutively overexpressing RAC3 by sta-
ble transfection and control non-tumoral cells transfected with an empty vector. The HeLa and T47D tumoral cells 
that naturally overexpress RAC3 were used as positive control. 
We found that TNF potentiated RAC3-induced mesenchymal transition, involving an increased E-Cadherin down-
regulation, Vimentin and SNAIL upregulation and enhanced migratory behavior. Moreover, concerning the mo-
lecular mechanisms by which TNF potentiates the RAC3 transforming action, they involve the IKK activation, 
which in addition induced the -Catenin transactivation.  
Our results demonstrate that although RAC3 overexpression could be a signal strong enough to induce cancer stem 
cells, the inflammatory microenvironment may be playing a key role contributing to the migratory and invasive 
phenotype required for metastasis and cancer persistence. 
 
Keywords: RAC3, cancer stem cells, mesenchymal cells, TNF-malignant transformation 
 
 
 
INTRODUCTION 
RAC3 (also known as SRC-3, AIB1, 
ACTR, p/CIP,TRAM-1), originally identified 
as a nuclear receptor coactivator and member 
of the p160 nuclear receptor coactivator’s 
family (Leo and Chen, 2000) is currently con-
sidered an oncogene (Ma et al., 2011; Torres-
Arzayus et al., 2004).  
Although it was first described as a mole-
cule overexpressed in breast tumors (Yan et 
al., 2006), it was later discovered as an NF-
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B coactivator (Werbajh et al., 2000) overex-
pressed in a broad spectrum of tumors 
(Gnanapragasam et al., 2001; Henke et al., 
2004; Sakakura et al., 2000) and having addi-
tional cytoplasmic functions non-related to its 
histone acetylase activity (Colo et al., 2008; 
Ma et al., 2011). 
In fact, RAC3 is an oncogene that contrib-
utes to tumor development acting as a nuclear 
receptor coactivator of several transcription 
factors (Liao et al., 2002; Wang et al., 2013; 
Yan et al., 2006) that control the expression 
of genes related to cell cycle and proliferation 
(Louie et al., 2006; Planas-Silva et al., 2001; 
Rubio et al., 2006; Torres-Arzayus et al., 
2004; Zhou et al., 2003), inhibition of apopto-
sis (Colo et al., 2007, 2008)) and autophagy 
(Fernandez Larrosa et al., 2012). However, 
additional functions related to tumor progres-
sion and metastasis development (Qin et al., 
2008; Wang et al., 2013), such as metallopro-
teinases expression (Qin et al., 2008), cell mi-
gration and epithelial-mesenchymal transition 
(EMT) (Tomar and Schlaepfer, 2010; Wang 
et al., 2013) have also been described and at-
tributed to the RAC3 splicing variant Delta 4-
SRC3 (Long et al., 2010). Interestingly, sev-
eral of these processes are positively regu-
lated by growth factors (Bedi et al., 2014) and 
inflammatory cytokines as TNF (Dong et al., 
2007; Rubio et al., 2006). In addition, some 
genes involved in the control of cell cycle, 
proliferation, apoptosis, cell adhesion and tu-
mor progression are targets of NF-B, a tran-
scription factor that is activated under inflam-
matory conditions (Baldwin, 2001; Guttridge 
et al., 1999; Hinz et al., 1999; Lin and Karin, 
2003). Moreover, we have recently demon-
strated that inflammatory cytokines upregu-
late RAC3 expression levels both in vitro and 
in vivo, through a direct action of NF-B on 
the RAC3 gene promoter (Alvarado et al., 
2014). 
In addition to its role as an oncogene, it 
was recently demonstrated that RAC3 expres-
sion is required in order to preserve the plu-
ripotency and self-renewal of stem cells 
(Percharde and Azuara, 2012; Percharde et 
al., 2012). In normal healthy tissues, the 
RAC3 expression is downregulated in mature 
and differentiated cells, suggesting that 
changes in its expression levels may play a 
critical role in development. In this regard, the 
EMT plays a key role not only in tumor pro-
gression and metastasis spreading, but also in 
morphogenesis during embryonic develop-
ment and tissue repair (Gonzalez and Medici, 
2014). In this last case, inflammation usually 
accompanies the process. 
Most of the studies that allowed to define 
RAC3 as an oncogene were performed in 
models where it is naturally overexpressed, 
such as cell lines, tumors and transgenic or 
knockout mice (Xu and Li, 2003). Although 
the effect of RAC3 overexpression in non-tu-
moral cells has not been deeply investigated 
up to date, we have previously demonstrated 
that RAC3 overexpression as a unique 
change, in the non-tumoral human embryonic 
kidney cell line (HEK293) gives to these cells 
the ability to grow in soft agar forming colo-
nies (Rubio et al., 2012) and to induce cancer 
stem cells (CSC) (Panelo et al., 2018). 
In this work, we investigated the role of 
TNF stimulation over the RAC3 overexpres-
sion-induced tumoral transformation using an 
original non-tumoral cell model. 
 
MATERIALS AND METHODS 
Cell culture and reagents 
The human embryonic kidney HEK293, 
the human tumoral HeLa and T47D cells were 
maintained in DMEM (Gibco Laboratories, 
Grand Island, NY) supplemented with 10 % 
fetal calf serum (FCS) (Invitrogen), penicillin 
(100 U/ml) and streptomycin (100 g/ml). 
Cells were maintained at 37 °C in a humidi-
fied atmosphere with 5 % CO2. Unless stated 
otherwise, all reagents were obtained from 
Sigma Chemical co. Bs. As., Argentina or 
Santa Cruz Biotechnology, USA. 
 
Expression vectors and reporter plasmids 
HEK293 cells were transfected with a 
RAC3 expression vector pCMV-Tag 2B-
RAC3 (RAC3) or with empty vector (EV) and 
selected for stable expression with Neomycin. 
The tumoral cell lines were transfected with 
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an expression vector for shRNA-RAC3 
(pRV-GFP-puromycin) or the scramble con-
trol, as previously described in our laboratory 
and selected for stable expression with puro-
mycin (Panelo et al., 2018). 
Reporter plasmids containing the consen-
sus sequence for NF-B binding (B-Luc), 
TCF binding (TOPFlash TCF/-Cat-Luc) and 
the IBss expression vector carrying the mu-
tated IB at Ser32 and Ser36 to prevent phos-
phorylation and proteolysis were used as pre-
viously described (Fernandez Larrosa et al., 
2012; Rubio et al., 2006; Werbajh et al., 
2000). 
 
Immunofluorescence 
Immunofluorescence was performed as 
previously described (Colo et al., 2008). 
Briefly, HEK293 RAC3 or EV transfectants 
were seeded on glass coverslips onto 24-well 
plates in DMEM medium containing 10 % 
FBS and 24 h later it was replaced by fresh 
medium and stimulated or not with TNF 20 
ng/ml, sulfasalazine 250 M or TNF plus sul-
fasalazine (30’ before of TNF treatment), dur-
ing 24 h or as indicated. Then, the cells were 
fixed with formaldehyde 37 %, permeabilized 
with PBS-Triton 0.2 %, blocked with 10 % 
FBS and incubated 2 h at room temperature 
with 5 g/ml of anti--Catenin antibody 
(sc:65480) (Santa Cruz Biotechnology). Fi-
nally, coverslips were incubated with rhoda-
mine conjugated secondary antibody and vis-
ualized with a fluorescence microscope 
Olympus BX51 and photographed at 1000X 
magnification. 
 
Western blot analysis 
Western blot assays were performed as 
previously described (Alvarado et al., 2014). 
Briefly, total proteins were obtained from 
HEK293 EV or RAC3 cells stimulated or not 
for 24 h with four different treatments as de-
scribed above. Proteins were separated on 
8 % SDS-PAGE, and electro-transferred to a 
nitrocellulose membrane, which was blocked 
for nonspecific binding with TBS 5 % milk 
and 0.05 % Tween-20 (T-TBS) and incubated 
overnight in T-TBS/0.5 % BSA with 0.5 
g/ml of anti-Vimentin, anti-E-Cadherin, or 
anti--Catenin primary antibodies. Subse-
quently, membranes were washed and incu-
bated for 1 h with a HRP-conjugated second-
ary antibody, developed by chemilumines-
cence (Santa Cruz Biotechnology). 
 
qPCR assay 
qPCR assay was performed as previously 
described (Alvarado et al., 2014). Briefly, to-
tal RNA was isolated from HEK293 transfect-
ants treated as described above by using the 
TRIzol protocol (Invitrogen). Reverse tran-
scription was carried out by using the Super-
Script II kit (Invitrogen) following the manu-
facturer’s instructions. For gene expression 
analysis, qPCR was performed by using se-
quence-specific primers for: 
RAC3: (FW: aagtgaagagggatctgga,  
RV: cagatgactaccatttgagg) 
Vimentin: (FW: gaacctgagggaaactaatctg, 
RV: ctgagaagtttcgttgataacc) 
E-Cadherin: (FW: tggtcaaagagcccttactg, 
RV: caagtcaaagtcctggtcct) 
Snail: (FW: cttccagcagccctacgac,  
RV: cggtggggttgaggatct)  
MMP2: (FW: ccagaataccatcgagacca,  
RV: gtagccaatgatcctgtatgtg) and 
GADPH: (FW: tctcctctgacttcaacagc,  
RV: gttgtcataccaggaaatga) as an internal con-
trol. 
 
Luciferase assays 
The assay was performed as previously 
described (Alvarado et al., 2014). Briefly, 
HEK293 EV or RAC3 cells were plated in 24-
well plates 24 h prior to transfection at a den-
sity of 2.5x105 cells/well. Cells were transi-
ently transfected with a total of 0.2 µg of 
DNA (0.1 µg of TOPFlash TCF/β-Cat-Luc, 5 
ng RSV-β Gal as the control for transfection 
efficiency and in some experiments, plus 
IκBss) using the calcium phosphate precipita-
tion method. The medium was replaced after 
7 h and cells were stimulated as described 
above. 
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The assays for luciferase and -galacto-
sidase activity were performed after 48 h of 
treatment using the appropriate substrates fol-
lowing the manufacturer’s protocols 
(Promega Corp. USA). The luciferase values 
were normalized to the control -galacto-
sidase (with constitutive expression and activ-
ity). 
 
Wound-healing sssay 
The assay was performed as previously 
described (Del Monaco et al., 2009). Briefly, 
1.5x106 cells/cm2 HEK293 EV or RAC3 were 
seeded onto 6-well plates in DMEM medium 
containing 10 % FBS, until achieving a con-
fluent cell layer. Monolayers were manually 
scraped with a 200-l pipette tip and washed 
with medium without serum to remove non-
adherent cells. Then, DMEM without FBS 
was added to attenuate cellular proliferation 
without impairing cell survival, following 
four different treatments: a control group with 
the drug vehicles, TNF 20 ng/ml, sulfasala-
zine 250 M, TNF 20 ng/ml plus sulfasala-
zine, (30’ before of TNF treatment). Cells 
were cultured at 37 ºC in humid air with con-
stant 5 % CO2. Wound scraping was consid-
ered time 0 and images of the wounded area 
were taken under the microscope at 24 h after 
the injury. Healing was quantified using Im-
age J 1.39 software (Image Processing and 
Analysis in Java, NIH, Bethesda, MD). Cell 
migration was expressed as the percentage of 
the area occupied by the migratory cells in the 
original cell-free wounded area. The results 
showed the average ± SD of three different 
cell assays. 
 
Metalloproteinases (MMP) activity assay 
MMP2 enzymatic activity was deter-
mined by zymography, as previously de-
scribed by Urtreger et al. (2005). Briefly, 
samples were run on 9 % SDS polyacryla-
mide slab gels containing 1 mg/ml of gelatin, 
under non-reducing conditions. After electro-
phoresis, gels were washed for 30 min using 
in 2.5 % Triton X-100 and subsequently incu-
bated for 48 h at 37 C in a buffer containing 
0.25M Tris-HCl pH 7.4, 1M NaCl, and 
25 mM CaCl2. For detection of non-specific 
activity, the gels were incubated in the same 
buffer solution but supplemented with 40 mM 
EDTA. After incubation, gels were fixed and 
stained with 0.5 % Coomassie Brilliant Blue 
G-250 in methanol/acetic acid/H2O 
(30:10:60). The white bands corresponding to 
MMP2 activity were determined and ana-
lyzed using Image J program after Coomassie 
Blue (Sigma) staining, where the densitome-
try values for each band was normalized to the 
protein contents of the conditioned medium as 
determined by Bradford assay.  
 
Statistics analysis  
At least three independent experiments 
were carried out in all cases. Results were ex-
pressed as the mean ± standard deviation 
(SD). The significance of differences between 
experimental conditions was determined us-
ing ANOVA and the Tukey–Kramer Multiple 
Comparisons Test for unpaired observations. 
 
RESULTS 
TNF contributes to RAC3 overexpression-
induced mesenchymal transformation of 
HEK293 cells 
We have previously found that RAC3 has 
a transforming role in HEK293 cells when is 
overexpressed by stable transfection, acquir-
ing not only the ability to grow in an anchor-
age-independent manner (Rubio et al., 2012) 
but also to initiate tumors when are inoculated 
to mice (Panelo et al., 2018).  
As previously demonstrated (Panelo et al., 
2018), although HEK293 cells express mod-
erated levels of the mesenchymal marker Vi-
mentin, they were significantly increased 
when RAC3 was overexpressed, while E-
Cadherin was significantly inhibited (Figure 
1A and B).  
TNF is an inflammatory cytokine that ac-
tivates several transduction signal pathways 
with multiple biological activities involved in 
oncogenesis, such as apoptosis, proliferation, 
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Figure 1: TNF contributes to RAC3 overexpression-induced mesenchymal transformation of 
HEK293 cells. qPCR analysis for Vimentin and E-Cadherin (A), Snail (C) and RAC3 (D) of total RNA 
from cells EV (empty vector) and RAC3 (overexpressing RAC3) HEK293 stimulated during 24 h with: 
vehicle (Basal), TNF 20 ng/ml (TNF), sulfasalazine 250 μM (SZ) and TNF plus sulfasalazine (TNF+SZ). 
In B, western blot for Vimentin and E-Cadherin showing one representative image and the relative den-
sitometric units (R.D.U) from three independent experiments. 
a: p < 0.05 respect to basal EV, b: p < 0.05 respect to basal RAC3, c: p < 0.05 respect to TNF stimulated RAC3, d: p < 0.05 
respect to cells transfected with empty vector
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angiogenesis, EMT (Colo et al., 2008; Dong 
et al., 2007; Lee et al., 2007; Rubio et al., 
2006) and involves the activation of NF-B. 
Interestingly, RAC3 is not only a NF-B co-
activator (Werbajh et al., 2000) but also a tar-
get of this transcription factor and is upregu-
lated by TNF (Alvarado et al., 2014). Thus, 
TNF could be contributing to cell transfor-
mation through the increase in RAC3 expres-
sion. Therefore, we then investigated the ef-
fect of TNF on the transforming role of RAC3 
overexpression. 
We found that TNF stimulation during 
24 h induces the increase of Vimentin levels 
and the inhibition of E-Cadherin in control 
cells when analyzed by qRT-PCR. These ef-
fects were significantly potentiated by RAC3 
overexpression, as determined by qPCR and 
Western Blot (Figure 1A and B). Moreover, 
the effects on E-Cadherin expression were 
correlated with changes in the expression pat-
tern of the E-Cadherin inhibitor SNAIL (Fig-
ure 1C). Figure 1D shows that cells trans-
fected with the RAC3 expression vector con-
stitutively overexpress this molecule. 
TNF activates IKK, which phosphorylates 
IB leading the activation of NF-B and other 
substrates such as RAC3 (Wahl et al., 1998; 
Wu et al., 2002). In order to investigate 
whether this transduction signal may be in-
volved in the effects of RAC3 and TNF, we 
performed the same experiments in the pres-
ence of sulfasalazine (SZ) a specific IKK in-
hibitor. We found that SZ addition signifi-
cantly inhibited the TNF-induced modulation 
of Vimentin (Fig 1A and B) and E-Cadherin 
(Figure 1A and B right panel) having a minor 
effect on SNAIL in cells overexpressing 
RAC3 (Figure 1C). Interestingly, SZ shows to 
inhibit the transforming effect of RAC3 over-
expression in the absence of TNF stimulation, 
as detected for mRNA expression of Vi-
mentin, E-Cadherin (Figure 1A) and SNAIL 
(Figure 1C). These results demonstrate that 
TNF potentiates the transforming role of 
RAC3 overexpression. Concerning the sig-
naling, although both of them involve the NF-
B activation pathway, additional signals 
could not be excluded. 
Then we investigated if the RAC3-in-
duced increase of metalloproteinases produc-
tion could be also potentiated by TNF. We 
found that metalloproteinase 2 was signifi-
cantly increased under simultaneous RAC3 
overexpression and TNF stimulation as deter-
mined by qPCR (Figure 2A) and zymography 
assays (Figure 2B). 
As observed for mesenchymal transition, 
the effect of TNF on metalloproteinases pro-
duction was significantly affected by IKK in-
hibition in all the lines.  
 
TNF stimulation potentiates RAC3  
overexpression induced cell motility 
Cancer propagation requires the migration 
and invasion of CSC and this is promoted by 
RAC3 overexpression (Panelo et al., 2018). 
Therefore, as a biological correlation of the 
transformation induced by RAC3 overexpres-
sion and TNF stimulation, we analyzed the 
migratory potential of both cell clones stimu-
lated or not by this cytokine. 
Figure 2C shows that although TNF stim-
ulation was unable to induce migration on 
HEK293 having low normal levels of RAC3, 
it potentiated the migration induced by RAC3 
overexpression. 
In order to validate these results in tu-
moral cells that naturally overexpress RAC3, 
we analyzed and compared the effect of TNF 
when RAC3 levels were downregulated by 
shRAC3 expression in HeLa (Figure 2D) and 
T47D (Figure 2E) cells. As shown, the poten-
tiating effect of TNF was similar to that ob-
served in HEK293 cells and diminished when 
RAC3 was downregulated. Figure 2F-G 
shows that cells transfected with the shRAC3 
expression vector, effectively express re-
duced levels of the coactivator, in agreement 
with the previously established model using 
these cells and the same vector (Panelo et al., 
2018). Interestingly, the inhibition of NF-B 
activity by SZ totally blocked migration. 
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Figure 2: TNF stimulation potentiates RAC3 overexpression-induced cell migration. MMP2 ex-
pression was determined by qPCR (A) and activity by zimography assays (B), where the down panel 
image corresponds to one representative assay from three. The diagram bars show the average +/- SD 
of wound coverage compared to time 0 and relative to basal EV in HEK293 (C), HeLa (D) and T47D 
(E). qPCR assays show a significant inhibition of RAC3 expression levels in HeLa (F) and T47D (G) 
stably expressing shRAC3. 
a: p < 0.05 respect to basal EV, b: p < 0.05 respect to basal RAC3, c: p < 0.05 respect to TNF stimulated RAC3, d: p < 0.05 
respect to basal scramble (SC), e: p < 0.05 respect to TNF stimulated SC, f: p < 0.05 respect to TNF stimulated shRAC3, *p < 
0.01 respect to SC. 
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TNF stimulation together with RAC3  
overexpression induce both -catenin  
nuclear translocation and TCF/-Catenin 
transcriptional activity 
In addition to its structural role in adher-
ent junctions, E-Cadherin mediates the dy-
namic of β-Catenin, which act as a transcrip-
tion factor serving as a coactivator of the 
Tcf/Lef family of DNA-binding proteins (Du 
and Geller, 2010). In the nucleus, the β-
Catenin transcriptional activity involves the 
expression control of genes related to onco-
genesis, proliferation, differentiation, and 
EMT (MacDonald et al., 2009), interestingly, 
similar to the biological functions of NF-B. 
In view that RAC3 overexpression down-
regulates the E-Cadherin and TNF potentiates 
this effect, we decided to investigate how 
these signalings affect the β-Catenin and NF-
B transactivation. 
We investigated the subcellular localiza-
tion of β-Catenin in cells overexpressing or 
not RAC3. Our results demonstrate that while 
in control cells the cytoplasmic pools were 
detected close to the cell membrane, some nu-
clear translocation could be detected under 
RAC3 overexpression condition. Interest-
ingly, under TNF stimulation during 24 h, al-
most all the β-Catenin was localized in the nu-
clei of RAC3 overexpressing clones, having 
only a slight effect in control cells (Figure 3A 
upper panel). The nuclear translocation was 
inhibited in all the cases by addition of the 
IKK inhibitor SZ. 
Similar results were obtained in HeLa tu-
moral cells, which naturally overexpress 
RAC3 (Figure 3A, down panel). 
Although both NF-B and -Catenin 
pathways are involved in the control of EMT 
(Dong et al., 2007; Gonzalez and Medici, 
2014; MacDonald et al., 2009) previous pub-
lished works suggest a mutual antagonism 
(Chang et al., 2013; Du and Geller, 2010; 
MacDonald et al., 2009). Therefore, we ana-
lyzed the TCF/-Catenin-dependent tran-
scriptional activity using a specific reporter 
assay. 
 
Figure 3: TNF stimulation together with RAC3 
overexpression induce the β-catenin nuclear 
translocation and transcriptional activity of 
TCF/β-catenin complex 
A. Inmunofluorescence analysis of β-Catenin in 
HEK293 (upper panels) and HeLa (bottom pan-
els) stimulated during 24 h with: vehicle (Basal), 
TNF 20 ng/ml (TNF), sulfasalazine 250 μM (SZ) 
and TNF plus sulfasalazine (TNF+SZ). B and C-
Reporter assays for TCF/β-Catenin-Luc. The bar 
diagram shows the average relative light units 
(RLU) of HEK293 (B) and HeLa (C) stimulated 
with vehicle (Basal), TNF 20 ng/ml, sulfasalazine 
250 μM (SZ), TNF plus sulfasalazine (TNF+SZ) 
and normalized respect to the β-galactosidase ac-
tivity at each case. 
a: p < 0.05 respect to basal RAC3, b: p < 0.05 respect to TNF 
stimulated RAC3, c: p < 0.05 respect to basal SC, d: p < 0.05 
respect to TNF stimulated SC. 
 
 
As shown in Figure 3B the TCF/-
Catenin-mediated transcriptional activity was 
significantly induced only under TNF stimu-
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lation and RAC3 overexpressing cells, as ob-
served in the originally non-tumoral HEK293 
and the tumoral HeLa cells (Figure 3C). In ad-
dition, we found that inhibition of NF-B ac-
tivation by SZ and transfection with IBss 
(data not shown) completely blocked the -
Catenin transactivation in agreement with its 
effect on -Catenin nuclear translocation.  
Taken together all these results demon-
strate that the transforming signaling induced 
by TNF under RAC3 overexpression involves 
at least, the activation of TCF/-Catenin tran-
scriptional activity, in an IKK-dependent 
pathway. 
 
DISCUSSION 
Most of the changes in the gene expres-
sion pattern involved in EMT have been re-
lated to epigenetic regulation (Bedi et al., 
2014). In fact, the EMT is required for cell 
migration and invasion and implies a quick 
and efficient reversibility when the mesen-
chymal cells find a new niche where to differ-
entiate and develop a secondary tumoral focus 
in the case of metastasis, as well as new tis-
sues in embryonal development.  
Certain epigenetic changes in chromatin 
structure can occur through the exchange of 
variant histones or assembly and disassembly 
of chromatin structure via histone chaperones, 
or through chromatin remodeling proteins. 
Substantial changes in epigenetic modificat-
ions occur to different degrees during various 
developmental processes such as germ cell 
development and stem cell differentiation as 
well as during pathologic processes such as 
tumorigenesis (Bedi et al., 2014). 
RAC3, originally described as a nuclear 
receptor coactivator and currently considered 
as an oncogene (Ma et al., 2011; Torres-
Arzayus et al., 2004), is a molecule that in ad-
dition to some cytoplasmic functions (Colo et 
al., 2008), has an intrinsic histone acetyl-
transferase activity (HAT) and the ability to 
recruit additional chromatin modifier en-
zymes like methylases and another HAT fac-
tors (Liao et al., 2002). Therefore, when 
RAC3 is recruited by specific nuclear tran-
scription factors, its principal function in the 
nucleus is chromatin remodeling and epige-
netic control of gene expression. 
RAC3 overexpression usually accompa-
nies tumor development which involves sev-
eral mutations and chromosome aberrations. 
However, we have previously demonstrated 
that RAC3 overexpression as a unique ge-
nomic change introduced in non-tumoral cells 
may induce CSC (Panelo et al., 2018). In this 
work, we found that constitutive RAC3 over-
expression affects the cytoskeletal structure, 
cell motility, and the activation of at least two 
signal transduction pathways strongly in-
volved in tumorigenesis, metastasis and em-
bryonic development (Baldwin, 2001; Chang 
et al., 2013; Dong et al., 2007; Gonzalez and 
Medici, 2014; Lin and Karin, 2003; 
MacDonald et al., 2009). Thus, we found that 
RAC3 overexpression promotes the increase 
of transcriptional activity not only of NF-B 
as previously described (Werbajh et al., 2000) 
but also of -Catenin mediated transcription. 
The nuclear translocation and transactivation 
of β-Catenin can be induced by the Wnt-β-
Catenin pathway; however, β-Catenin may 
also bind E-Cadherin sharing the same do-
mains that are involved in the binding to 
Tcf/Lef transcription factors. Therefore, when 
the levels of E-Cadherin are high, β-Catenin 
is recruited to the transmembrane pool of pro-
teins, inhibiting its nuclear translocation and 
antagonizing the Wnt-β-Catenin pathway. In 
addition to its nuclear or transmembrane pool, 
β-Catenin is also under a constitutive turno-
ver, as part of a cytoplasmic complex where 
is phosphorylated and degraded (MacDonald 
et al., 2009). 
Although several inflammatory and not 
inflammatory signals can activate NF-B, in 
the case of -Catenin, the turnover and tran-
scriptional activity are mainly regulated by 
Wnt activation pathway (MacDonald et al., 
2009).  
The tumor microenvironment plays an 
important role in promoting cancer progres-
sion through EMT induction, invasiveness 
and metastasis and most tumors are infiltrated 
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by immune cells that produce inflammatory 
cytokines.  
TNF is an inflammatory cytokine that ac-
tivates several transduction signal pathways 
with multiple biological activities involved in 
oncogenesis, such as apoptosis, proliferation, 
angiogenesis and EMT (Colo et al., 2008; 
Dong et al., 2007; Lee et al., 2007; Rubio et 
al., 2006) and involves the activation of NF-
B. Interestingly, RAC3 is not only a NF-B 
coactivator (Werbajh et al., 2000) but also a 
target of this transcription factor. Therefore, 
TNF is able to induce the increase of RAC3 
gene expression (Alvarado et al., 2014). Thus, 
TNF could be contributing to cell transfor-
mation through the increase in RAC3 expres-
sion, although additional signals could not be 
excluded (Figure 4). Afterward, in this work, 
we investigated the role of TNF on RAC3 ef-
fects, in an experimental model where RAC3 
is constitutively overexpressed, in order to be-
come independent of the endogenous RAC3 
increase that could be induced by this cyto-
kine. We found that TNF potentiates the 
transforming effects of RAC3 overexpres-
sion, contributing to the mesenchymal pheno-
type. Moreover, the maximal cell migration, 
-Catenin nuclear localization and transcrip-
tional activity were observed in conditions of 
RAC3 overexpression together with TNF 
stimulation. These observations are in agree-
ment with previous reports concerning the 
ability of TNF to activate the Wnt pathway 
(Coskun et al., 2014) in addition to the posi-
tive effect of IKK on the -Catenin tran-
scriptional activity (Du and Geller, 2010). In 
this regard, we observed that most of the 
transforming effects of RAC3 overexpression 
alone or together with TNF stimulation were 
significantly downregulated by addition of 
the specific IKK inhibitor SZ, including the -
Catenin transcriptional activity. Therefore, 
although SZ inhibits the activation of several 
IKK substrates including NF-B, our results 
suggest that activation of this transcription 
factor is a key element for RAC3 plus TNF-
induced transformation. However, we found 
that some transforming effects of RAC3 over-
 
Figure 4: The interplay of RAC3 overexpression and TNF as part of a positive feedback contrib-
utes to tumor development 
The increase of RAC3 that could be induced by inflammatory cytokines is a mesenchymatic transform-
ing signal that increases Vimentin, donwregulates E-Cadherin expression, enhances β-catenin-depend-
ent transcriptional activity and cell migration. These effects are potentiated by TNF and some of them 
are dependent of NF-κB. However, additional cytoplasmic RAC3 actions or NF-κB independent effects 
of this coactivator could not be excluded. 
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expression without TNF stimulation were 
also inhibited by SZ, as observed for mesen-
chymal transformation (Figure 1) and cell mi-
gration (Figure 2). Although these results are 
in agreement with the previous work demon-
strating that RAC3 is an IKK target (Wu et al., 
2002), additional signals IKK-independent, 
downstream of RAC3 could not be excluded. 
Taken together all our results, we demon-
strate that the increase of RAC3 expression 
levels affects specific transduction signals by 
which contributes to the mesenchymal transi-
tion and the migratory and invasive behavior 
of these cells. Interestingly, this transfor-
mation could be potentiated by inflammatory 
cytokines like TNF which share some of the 
transduction signals affected by RAC3, acti-
vating IKK and NF-B, suggesting that prob-
ably this crosstalk could be relevant in pri-
mary tumors that overexpress RAC3, usually 
infiltrated by cells of the immune system that 
produce inflammatory cytokines in situ, fa-
voring the migration and metastasis and in-
creasing the malignancy. 
Regarding our present findings, we may 
conclude that while the overexpression of 
RAC3 is a mesenchymal/CSC transforming 
signal, its biological activity is potentiated by 
TNF, suggesting that inflammatory tumoral 
microenvironment may be playing a key role 
in the control of cancer initiation and propa-
gation, contributing to maintain the mesen-
chymal properties of RAC3-induced CSC. 
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